Rolf Bohlmann
Overview
Explore the profile of Rolf Bohlmann including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
169
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lucking U, Kosemund D, Bohnke N, Lienau P, Siemeister G, Denner K, et al.
J Med Chem
. 2021 Jul;
64(15):11651-11674.
PMID: 34264057
Selective inhibition of exclusively transcription-regulating positive transcription elongation factor b/CDK9 is a promising new approach in cancer therapy. Starting from atuveciclib, the first selective CDK9 inhibitor to enter clinical development,...
2.
Schulze V, Klar U, Kosemund D, Wengner A, Siemeister G, Stockigt D, et al.
J Med Chem
. 2020 Apr;
63(15):8025-8042.
PMID: 32338514
Inhibition of monopolar spindle 1 (MPS1) kinase represents a novel approach to cancer treatment: instead of arresting the cell cycle in tumor cells, cells are driven into mitosis irrespective of...
3.
Lucking U, Scholz A, Lienau P, Siemeister G, Kosemund D, Bohlmann R, et al.
ChemMedChem
. 2017 Sep;
12(21):1776-1793.
PMID: 28961375
Selective inhibition of exclusively transcription-regulating PTEFb/CDK9 is a promising new approach in cancer therapy. Starting from lead compound BAY-958, lead optimization efforts strictly focusing on kinase selectivity, physicochemical and DMPK...
4.
Hartung I, Hammer S, Hitchcock M, Neuhaus R, Scholz A, Siemeister G, et al.
Bioorg Med Chem Lett
. 2015 Nov;
26(1):186-93.
PMID: 26611920
Recently, we had identified an unexplored pocket adjacent to the known binding site of allosteric MEK inhibitors which allowed us to design highly potent and in vivo efficacious novel inhibitors....
5.
Otto C, Fuchs I, Altmann H, Klewer M, Schwarz G, Bohlmann R, et al.
J Steroid Biochem Mol Biol
. 2008 Jul;
111(1-2):95-100.
PMID: 18606537
Estrogen receptor (ER) ligands that are able to prevent postmenopausal bone loss, but have reduced activity in the uterus and the mammary gland might be of great value for hormone...
6.
Schaefer O, Bohlmann R, Schleuning W, Schulze-Forster K, Humpel M
J Agric Food Chem
. 2005 Apr;
53(8):2881-9.
PMID: 15826034
Seven carboxylic acid haptens of 8-prenylnaringenin (8-PN) were synthesized, coupled to cationized bovine serum albumin, and employed to raise specific antisera in rabbits. Two linkers of different lengths (C3H6COOH and...
7.
Hoffmann J, Bohlmann R, Heinrich N, Hofmeister H, Kroll J, Kunzer H, et al.
J Natl Cancer Inst
. 2004 Feb;
96(3):210-8.
PMID: 14759988
Background: Antiestrogens of the selective estrogen receptor modulator (SERM) type, such as tamoxifen, have two major limitations: their mixed agonist and antagonist profile and the development of tumor resistance. We...
8.
Schaefer O, Humpel M, Fritzemeier K, Bohlmann R, Schleuning W
J Steroid Biochem Mol Biol
. 2003 Apr;
84(2-3):359-60.
PMID: 12711023
No abstract available.